Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30.

Article  Google Scholar 

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. A Cancer J Clinic. 2024;74(3):229–63.

Article  Google Scholar 

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Meryñeros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer today, Lyon, France (2024). https://gco.iarc.who.int/today

Fossella F, DeVore R, Kerr R, et al. Randomized phase iii trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2003;21(16):3016–24.

Article  Google Scholar 

Hanna N, Shepherd F, Fossella F, et al. Randomized phase iii trial of docetaxel versus pemetrexed in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22(9):1589–97.

Article  Google Scholar 

Sudhakar A. History of cancer, ancient and modern treatment methods. Cancer Science & Therapy. 2009;1(02):i–iv.

Article  Google Scholar 

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell. 2011;144(5):646–74.

Kinnel B, Singh SK, Oprea-Ilies G, Singh R. Targeted therapy and mechanisms of drug resistance in breast cancer. Cancers. 2023;15(4):1320.

Article  Google Scholar 

Ghita M, et al. A computational model for optimizing chemotherapy scheduling using reinforcement learning. Comput Biol Med. 2022;143:105241.

Google Scholar 

Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233.

Article  Google Scholar 

Alam MS, Hossain MA, Algoul S, Majumader M, Al-Mamun MA, Sexton G, et al. Multi-objective multi-drug scheduling schemes for cell cycle specific cancer treatment. Comput Chem Eng. 2013;58:14–32.

Article  Google Scholar 

Ohe Y, Yamamoto N, Asami K, et al. Triplet chemotherapy with cisplatin, docetaxel, and irinotecan in patients with advanced non-small-cell lung cancer: a phase ii study. Lung Cancer. 2010;67(1):50–5.

Google Scholar 

Kubota K, Ichinose Y, Ohe Y, et al. Phase ii study of triplet chemotherapy including cisplatin, docetaxel, and irinotecan for recurrent or refractory non-small cell lung cancer. Jpn J Clin Oncol. 2012;42(7):596–602.

Google Scholar 

Yang C-Y, Shiranthika C, Wang C-Y, Chen K-W, Sumathipala S. Reinforcement learning strategies in cancer chemotherapy treatments: A review. Comput Methods Programs Biomed. 2023;229:107280.

Article  Google Scholar 

Sbeity H, Younes R. Review of optimization methods for cancer chemotherapy treatment planning. J Comput Sci Syst Biol. 2015;8(2):74.

Article  Google Scholar 

Hong N, Sun G, Zuo X, Chen M, Liu L, Wang J, et al. Application of informatics in cancer research and clinical practice: Opportunities and challenges. Cancer Innovation. 2022;1(1):80–91.

Article  Google Scholar 

Martin RB. Optimal control drug scheduling of cancer chemotherapy. Automatica. 1992;28(6):1113–23.

Article  MathSciNet  Google Scholar 

Eisen M. Mathematical models in cell biology and cancer chemotherapy, 30, Springer Science & Business Media, 2013.

Algoul S, Alam MS, Hossain MA, Majumder M, Feedback control of chemotherapy drug scheduling for phase specific cancer treatment, in,. IEEE Fifth Int Conf Bio-Inspired Comput: Theories Appl (BIC-TA). IEEE. 2010:1443–50.

Pachauri N, Yadav J, Rani A, Singh V. Modified fractional order imc design based drug scheduling for cancer treatment. Comput Biol Med. 2019;109:121–37.

Article  Google Scholar 

Moradi H, Vossoughi G, Salarieh H. Optimal robust control of drug delivery in cancer chemotherapy: a comparison between three control approaches. Comput Methods Programs Biomed. 2013;112(1):69–83.

Article  Google Scholar 

Pachauri N, Suresh V, Kantipudi MP, Alkanhel R, Abdallah HA. Multi-drug scheduling for chemotherapy using fractional order internal model controller. Mathematics. 2023;11(8):1779.

Article  Google Scholar 

Shindi O, Kanesan J, Kendall G, Ramanathan A. The combined effect of optimal control and swarm intelligence on optimization of cancer chemotherapy. Comput Methods Programs Biomed. 2020;189:105327.

Article  Google Scholar 

Tse S-M, Liang Y, Leung K-S, Lee K-H, Mok TS-K. A memetic algorithm for multiple-drug cancer chemotherapy schedule optimization, IEEE Transactions on Systems, Man, and Cybernetics. Part B (Cybernetics). 2007;37(1):84–91.

Article  Google Scholar 

Panjwani B, Singh V, Rani A, Mohan V. Optimum multi-drug regime for compartment model of tumour: cell-cycle-specific dynamics in the presence of resistance. J Pharmacokinet Pharmacodyn. 2021;48(4):543–62.

Article  Google Scholar 

Padmanabhan R, Meskin N, Haddad WM. Reinforcement learning-based control of drug dosing for cancer chemotherapy treatment. Math Biosci. 2017;293:11–20.

Article  MathSciNet  Google Scholar 

Yauney G, Shah P. Reinforcement learning with action-derived rewards for chemotherapy and clinical trial dosing regimen selection, in: Machine Learning for Healthcare Conference, PMLR, 2018, pp. 161–226.

van Hasselt H. Double q-learning. Adv Neural Inf Process Syst. 2010;23:2613–21.

Google Scholar 

Hasselt H.V, Guez A, Silver D. Deep reinforcement learning with double q-learning, in: Proceedings of the AAAI conference on artificial intelligence, 30, 2016.